NDA 214938 · Biomarin Pharm
Voxzogo
Vosoritide · Subcutaneous
NovelAccelerated approvalOrphanCDER novel approval, Nov 19, 2021: To improve growth in children five years of age and older with achondroplasia and open epiphyses
Last checked: Nov 19, 2026Latest source record: Nov 4, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Nov 19, 2021
Approved uses
2
Original approval plus efficacy supplements
Registered trials
17
5 Phase 3, 3 recruiting
FAERS reports
1
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 25, 2025.
VOXZOGO is indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). VOXZOGO is a C type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1 )
Mechanism: In patients with achondroplasia, endochondral bone growth is negatively regulated due to a gain of function mutation in fibroblast growth factor receptor 3 ( FGFR3 ). Binding of vosoritide to natriuretic peptide receptor-B (NPR-B) antagonizes FGFR3 downstream signaling by inhibiting the extracellular signal-regulated kinases 1 and 2 (ERK1/2) in the mitogen-activated protein kinase (MAPK) pathway at the level of rapidly accelerating fibrosarcoma serine/threonine protein kinase (RAF-1). As a result, vosoritide, like CNP, acts as a positive regulator of endochondral bone growth as it promotes...
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 20, 2023 Supplement 2 · Efficacy OrphanLabelLetterReview
- Nov 19, 2021 Original approval · Type 1 - New Molecular Entity NovelAccelerated approvalOrphanLabelLetterReview
3 products under this application
- VOXZOGO · VOSORITIDE 0.56MG/VIAL · POWDER, SUBCUTANEOUS · Prescription
- VOXZOGO · VOSORITIDE 1.2MG/VIAL · POWDER, SUBCUTANEOUS · Prescription
- VOXZOGO · VOSORITIDE 0.4MG/VIAL · POWDER, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Vosoritide" as an intervention, any sponsor and status, largest first.
- Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With AchondroplasiaPivotal-lookingRecruiting
BioMarin PharmaceuticalBioMarin (BMRN)
NCT07441876 · 160 participants (planned) · Start Apr 20, 2026 · Primary completion Jun 2029
Drug: BMN 333; Vosoritide Injection [Voxzogo] · For: Achondroplasia
Sites: Oakland, California; Wilmington, Delaware; Chicago, Illinois · 28 sites in all
- Long-Term Extension Study of Vosoritide to Treat Children With HypochondroplasiaPivotal-lookingEnrolling by invitation
BioMarin PharmaceuticalBioMarin (BMRN)
NCT07073014 · 140 participants (planned) · Start Jun 20, 2025 · Primary completion Oct 2044
Drug: Vosoritide · For: Hypochondroplasia
Sites: Phoenix, Arizona; Oakland, California; Wilmington, Delaware · 30 sites in all
- A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With AchondroplasiaPivotal-lookingCompleted
BioMarin PharmaceuticalBioMarin (BMRN)
NCT03197766 · 121 participants · Start Dec 12, 2016 · Primary completion Oct 30, 2019
Drug: BMN 111; Placebo · For: Achondroplasia
Sites: Oakland, California; Torrance, California; Wilmington, Delaware · 24 sites in all
- An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With AchondroplasiaPivotal-lookingActive, not recruiting
BioMarin PharmaceuticalBioMarin (BMRN)
NCT03424018 · 119 participants · Start Dec 12, 2017 · Primary completion Jun 2031
Drug: BMN 111 · For: Achondroplasia
Sites: Oakland, California; Torrance, California; Wilmington, Delaware · 24 sites in all
- A Phase 2 Study of Vosoritide in Children With Idiopathic Short StaturePivotal-lookingRecruiting
BioMarin PharmaceuticalBioMarin (BMRN)
NCT06382155 · 100 participants (planned) · Start Oct 21, 2024 · Primary completion Jun 2026
Drug: Vosoritide Injection; Human Growth Hormone and 1 more · For: Idiopathic Short Stature
Sites: California City, California; Los Angeles, California; Oakland, California · 47 sites in all
- Interventional Study of Vosoritide for the Treatment of Children With HypochondroplasiaPivotal-lookingCompleted
BioMarin PharmaceuticalBioMarin (BMRN)
NCT06455059 · 81 participants · Start Jun 17, 2024 · Primary completion Apr 23, 2026
Drug: Vosoritide; Placebo · For: Hypochondroplasia
Sites: Wilmington, Delaware; Washington D.C., District of Columbia; Chicago, Illinois · 23 sites in all
BioMarin PharmaceuticalBioMarin (BMRN)
NCT03583697 · 75 participants · Start Jun 13, 2018 · Primary completion Jan 26, 2022
Drug: BMN 111; Placebo · For: Achondroplasia
Sites: Oakland, California; Torrance, California; Wilmington, Delaware · 16 sites in all
- A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult VolunteersCompleted
BioMarin PharmaceuticalBioMarin (BMRN)
NCT01590446 · 74 participants (planned) · Start Feb 2012 · Primary completion Jun 2012
Drug: BMN 111; Normal Saline · For: Achondroplasia
Sites: Evansville, Indiana
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dose calculation error1
- product preparation error1
- product prescribing error1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Burden and Treatment of Achondroplasia: A Systematic Literature Review.
Murton MC, Drane ELA, Goff-Leggett DM, et al. · Adv Ther 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Real-world outcomes of vosoritide in achondroplasia: A systematic review and meta-analysis of multinational clinical evidence.
Albuquerque ALB, Dacoregio MI, Rodrigues CG, et al. · Genet Med 2026 · Systematic Review, Meta-Analysis
- Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial.
Savarirayan R, Tofts L, Irving M, et al. · Lancet 2020 · Clinical Trial, Phase III, Multicenter Study
- Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial.
Savarirayan R, Wilcox WR, Harmatz P, et al. · Lancet Child Adolesc Health 2024 · Clinical Trial, Phase II, Multicenter Study
- Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study.
Savarirayan R, Tofts L, Irving M, et al. · Genet Med 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study.
Savarirayan R, Irving M, Wilcox WR, et al. · Med 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: BioMarin
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.